Joseph C, Chassan J B, Koch M L
Ann Neurol. 1978 Feb;3(2):116-8. doi: 10.1002/ana.410030205.
Mortality rates for a group of patients in a collaborative multicenter study of levodopa (Larodopa) in the treatment of parkinsonism were compared with corresponding mortality rates in the general population adjusted for age and sex distribution in accordance with that of the parkinsonian patients under study. The death rate, conservatively adjusted for dropouts among parkinsonian patients, is estimated to be approximately 33% greater than that for the general population. This is in contrast to an earlier study of Hoehn and Yahr, prior to the advent of levodopa treatment, wherein the mortality rate for parkinsonian patients was shown to be in excess of that in the general population by a factor of 2.9, or nearly 200%.
在一项关于左旋多巴（美多巴）治疗帕金森病的多中心合作研究中，将一组患者的死亡率与根据所研究帕金森病患者的年龄和性别分布进行调整后的普通人群的相应死亡率进行了比较。经保守调整帕金森病患者中的失访情况后，估计死亡率比普通人群高出约33%。这与左旋多巴治疗出现之前Hoehn和Yahr的早期研究形成对比，在该研究中，帕金森病患者的死亡率比普通人群高出2.9倍，即近200%。
